More than three decades ago, Congress created the 340B program to help safety-net hospitals and clinics expand resources and care for underserved communities. By requiring pharmaceutical companies to ...
This approach would aim to raise the same amount of revenue that was previously generated by covered entities’ arbitrage of ...
The Well News on MSN
Bipartisan Senate Lawmakers Scrutinize 340B Program, Call for Reforms
WASHINGTON - A Senate health committee met last week to scrutinize the 340B Program, an initiative intended to foster the ...
Johnson & Johnson, Eli Lilly, Sanofi and Bristol Myers Squibb are suing the federal government over the future of their 340B drug rebate plans. The lawsuits reflect rising tensions among drugmakers, ...
AHA writes to express our strong support for this vital program that allows eligible hospitals to maintain, improve and expand access to essential services and medications for the patients and ...
The 340B Drug Pricing Program enacted in 1992 requires pharmaceutical manufacturers participating in the Medicaid program to provide statutorily defined discounts on "covered outpatient drugs" ...
The 340B Drug Pricing Program helps poor states like Kentucky. Bigstock Senate Bill 14 in the ongoing Kentucky legislative session relates to the federal 340B Drug Pricing Program. This program ...
The 340B Drug Pricing Program was created to help a targeted group of safety net providers care for low-income and uninsured patients. First enacted as part of the Veterans Healthcare Act of 1992, ...
On July 31, the US Department of Health and Human Services’ (HHS) Health Resources and Services Administration (HRSA) announced the availability of a new pilot program altering how pharmaceutical ...
This past September, a sub-agency of the Department of Health and Human Services (HHS) threatened to kick a pharmaceutical company out of Medicare because the company, in line with federal law, ...
The White House has proposed good and bad ideas to reduce drug costs. Among the better ones is a reform of the obscure 340B drug program, which enriches large hospitals at the expense of patients. Cue ...
Forbes contributors publish independent expert analyses and insights. Sally Pipes is a scholar and think tank CEO who writes on health care. "MFN reinforces the worst incentives in 340B, shifts costs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback